Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Ausztrália1. fázis

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

A legfontosabb adatok

Ki végzi
Janssen Research & Development, LLC
Hol
Adelaide (Ausztrália)A helyszín megnézéseMég 2 másik országban, 9 helyszínen
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
170 fő, tervezett
Kezdés
2026. ápr. 9.
Várható befejezés
2030. ápr. 15.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • JNJ-101684362 (HLD-0117)
A regiszteradat frissítve
2026. november 3.

Ki vehet részt

Életkor
18 év felett
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Female (assigned at birth), greater than or equal to (>=) 18 years old, and able to provide informed consent
  • Histologically confirmed metastatic or locally advanced breast cancer
  • Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist
  • Prior therapy including; Must have received at least one endocrine therapy in the metastatic setting; Must have received at least one cyclin-dependent kinase (CDK) 4/6i, either in the adjuvant and/or metastatic setting; For Part 1 and Part 2 Cohorts 2A, 2B, 2C, and 2D: Participants may have received up to two prior distinct cytotoxic regimens (for example, taxanes, antibody-drug conjugates (ADCs), etc.) in the metastatic setting, unless discussed and approved by the medical monitor; For Part 2 Cohort 2E: Participants must have received more than two prior distinct cytotoxic regimens (for example, taxanes, ADCs, etc.) in the metastatic setting
  • Radiologic disease progression on the most recent therapy
  • Patients must have disease evaluable per response evaluation criteria in solid tumors (RECIST) v1.1; For Part 1 and Part 2B, 2C, and 2E: Participants may have either evaluable or measurable disease per RECIST v1.1; For Part 2 Cohort 2A: Participants should have measurable soft tissue disease per RECIST v1.1; For Part 2 Cohort 2D: Participants should have evaluable but not measurable disease
  • Willingness to provide baseline and on-treatment tumor biopsies, unless not feasible or medically appropriate
  • For Part 1 and Part 2 (all cohorts):; Participants must have documented >=10% ER staining and human epidermal growth factor receptor 2 (HER2) negative (per american society of clinical oncology [ASCO] college of american pathologists [CAP] guidelines) on the most recent tumor biopsy sample obtained; For Part 2 Cohort 2B: Participants must have recent estrogen receptor 1 gene (ESR1) wild type from tumor or circulating tumor deoxy ribonucleic acid (ctDNA) testing performed after the most recent endocrine therapy prior to enrollment; For Part 2 Cohort 2C: Participants must have ESR1 mutation detected from tumor or ctDNA testing performed prior to enrollment
  • Eastern cooperative oncology group (ECOG) performance status 0-1 and life expectancy of at least 3 months
  • Adequate organ function Recovery from prior therapy-related toxicities to Grade <=1 (except alopecia; neuropathy and endocrinopathies <=Grade 2)
  • Ability to swallow oral medication and comply with study procedures
  • Stable dose (>=30 days) of bisphosphonates or denosumab, if applicable

Ki nem vehet részt

  • Participants with Inflammatory breast cancer or leptomeningeal disease or brain metastases, with the exception of patients with definitively treated brain metastases that are clinically stable and asymptomatic for >2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 mg prednisone or equivalent) for at least 2 weeks prior to start of study treatment
  • Ongoing corticosteroid use >10 mg/day (prednisone equivalent)
  • Recent anticancer or investigational therapy within 14 days (28 days for fulvestrant)
  • Major surgery within 28 days
  • Recent major bleeding or uncontrolled bleeding disorder
  • Significant cardiovascular disease within 6 months or ongoing uncontrolled cardiac conditions
  • Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed)
  • Uncontrolled renal, pancreatic, or liver disease (excluding stable conditions such as Gilbert's syndrome or liver metastases)
  • Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers)
  • Any condition that may interfere with safety or study compliance
  • Untreated or unstable spinal cord compression
  • Pregnancy or breastfeeding

Ez a vizsgálat jelenleg itt érhető el: Ausztrália.

Még 2 másik országban, 9 helyszínen

  • Cancer Research SAAdelaide, AusztráliaRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to find out the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of JNJ-101684362 (HLD-0117), to evaluate the safety of JNJ-101684362 (HLD-0117) , and how well the participants can tolerate it in Part 1 (dose escalation) of the study.

A vizsgálat csoportja

  • Arm 1A vizsgált kezelés

    JNJ-101684362 (HLD-0117): Participants with estrogen receptor positive (ER+) metastatic breast cancer (MBC) will receive JNJ-101684362 (HLD-0117) orally once daily as monotherapy in Part 1 until recommended dose(s) for expansion has been developed. Participants in Part 2 will receive JNJ-101684362 (HLD-0117) at the RP2Ds developed in Part 1.

    Kezelés: JNJ-101684362 (HLD-0117)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase 1 Study of JNJ-101684362 (HLD-0117) in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC)
A regiszteradat frissítve
2026. november 3.